Regeneron’s Libtayo Dosing Application Under FDA Review
A U.S. supplemental biologics license application for Libtayo dosing is under review, with a decision expected in March 2027.
A U.S. supplemental biologics license application for Libtayo dosing is under review, with a decision expected in March 2027.